JPWO2020146615A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146615A5 JPWO2020146615A5 JP2021539523A JP2021539523A JPWO2020146615A5 JP WO2020146615 A5 JPWO2020146615 A5 JP WO2020146615A5 JP 2021539523 A JP2021539523 A JP 2021539523A JP 2021539523 A JP2021539523 A JP 2021539523A JP WO2020146615 A5 JPWO2020146615 A5 JP WO2020146615A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- pyrrolo
- dihydro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 64
- 201000010099 disease Diseases 0.000 claims 32
- 208000035475 disorder Diseases 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 14
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 7
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 6
- 208000021709 Delayed Graft Function Diseases 0.000 claims 6
- 208000033626 Renal failure acute Diseases 0.000 claims 6
- 201000011040 acute kidney failure Diseases 0.000 claims 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 6
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- FBORMSYFVQSNPV-UHFFFAOYSA-N 1-[7-fluoro-5-(1-methylpyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-one Chemical compound CCC(=O)C1=NN2C(CC(C2=N1)F)C3=CN(N=C3)C FBORMSYFVQSNPV-UHFFFAOYSA-N 0.000 claims 2
- ZQVFZBINUZNLET-UHFFFAOYSA-N CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(COC(F)F)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O ZQVFZBINUZNLET-UHFFFAOYSA-N 0.000 claims 2
- MSWPUSCLYLQSOD-KBPBESRZSA-N CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O Chemical compound CC(N(C1)CC1C(C1=NN([C@@H](C[C@@H]2F)C3=CC=CC=C3)C2=N1)=O)=O MSWPUSCLYLQSOD-KBPBESRZSA-N 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 2
- UCBCDYATPTZCCC-UHFFFAOYSA-N [5-(3-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-cyclopropylmethanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CC=C4)Cl UCBCDYATPTZCCC-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- ADJGHHDLGNZOCP-UHFFFAOYSA-N cyclopropyl-(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound C1CC1C(=O)C2=NN3CCC(C3=N2)C4=CC=CC=C4 ADJGHHDLGNZOCP-UHFFFAOYSA-N 0.000 claims 2
- HXHYIBLISMREFM-GHMZBOCLSA-N cyclopropyl-[(5R,7R)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@H](C[C@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-GHMZBOCLSA-N 0.000 claims 2
- HXHYIBLISMREFM-QWRGUYRKSA-N cyclopropyl-[(5S,7S)-7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3[C@@H](C[C@@H](C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-QWRGUYRKSA-N 0.000 claims 2
- HXHYIBLISMREFM-UHFFFAOYSA-N cyclopropyl-[7-fluoro-5-(5-fluoropyridin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone Chemical compound C1CC1C(=O)C2=NN3C(CC(C3=N2)F)C4=CC(=CN=C4)F HXHYIBLISMREFM-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000037806 kidney injury Diseases 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- CLELLYLGVVWSNC-UHFFFAOYSA-N (2,2-dimethyl-3-oxabicyclo[3.1.0]hexan-1-yl)-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone Chemical compound CC1(C)OCC(C2)C12C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O CLELLYLGVVWSNC-UHFFFAOYSA-N 0.000 claims 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- UBGABCPJLOUPOD-UHFFFAOYSA-N CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O Chemical compound CC(C)(CO)C(C1=NN(C(CC2F)C3=CC=CC=C3)C2=N1)=O UBGABCPJLOUPOD-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- RYFGSKWVGYBXNB-UHFFFAOYSA-N N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 Chemical compound N#CC1=CC(C(C2)N3N=C(C(C4CC4)=O)N=C3C2F)=CC=C1 RYFGSKWVGYBXNB-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010053879 Sepsis syndrome Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 210000000609 ganglia Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791118P | 2019-01-11 | 2019-01-11 | |
| US62/791,118 | 2019-01-11 | ||
| PCT/US2020/012908 WO2020146615A1 (en) | 2019-01-11 | 2020-01-09 | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516651A JP2022516651A (ja) | 2022-03-01 |
| JPWO2020146615A5 true JPWO2020146615A5 (https=) | 2023-01-19 |
| JP2022516651A5 JP2022516651A5 (https=) | 2023-01-19 |
| JP7585205B2 JP7585205B2 (ja) | 2024-11-18 |
Family
ID=69528972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539523A Active JP7585205B2 (ja) | 2019-01-11 | 2020-01-09 | 二環式ピロロトリアゾールケトン化合物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12344612B2 (https=) |
| EP (1) | EP3908586B1 (https=) |
| JP (1) | JP7585205B2 (https=) |
| CN (1) | CN113302193A (https=) |
| AR (1) | AR119673A1 (https=) |
| TW (1) | TW202043229A (https=) |
| WO (1) | WO2020146615A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313986A1 (en) * | 2021-04-02 | 2024-02-07 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| WO2023225041A1 (en) | 2022-05-19 | 2023-11-23 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| RU2628616C2 (ru) | 2011-11-03 | 2017-08-21 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения пиперазина |
| EP2852584B1 (en) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
| CA2896187A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| PH12019502378A1 (en) | 2013-05-01 | 2022-05-11 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
| CA2907912A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| WO2015006280A1 (en) | 2013-07-10 | 2015-01-15 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| TWI763630B (zh) * | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| CN108602809B (zh) * | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| US11180493B2 (en) * | 2016-11-08 | 2021-11-23 | Cyclerion Therapeutics, Inc. | SGC stimulators |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US11098058B2 (en) * | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
| PE20211246A1 (es) * | 2017-10-11 | 2021-07-13 | Hoffmann La Roche | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
-
2020
- 2020-01-09 CN CN202080008933.9A patent/CN113302193A/zh active Pending
- 2020-01-09 AR ARP200100056A patent/AR119673A1/es unknown
- 2020-01-09 WO PCT/US2020/012908 patent/WO2020146615A1/en not_active Ceased
- 2020-01-09 EP EP20704652.5A patent/EP3908586B1/en active Active
- 2020-01-09 JP JP2021539523A patent/JP7585205B2/ja active Active
- 2020-01-09 TW TW109100698A patent/TW202043229A/zh unknown
-
2021
- 2021-07-08 US US17/371,001 patent/US12344612B2/en active Active
-
2025
- 2025-05-23 US US19/217,418 patent/US20250282788A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| JP7592784B2 (ja) | Ｊａｋ１阻害剤としてのピペリジン－４－イルアゼチジン誘導体 | |
| JP7010935B2 (ja) | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環 | |
| JP4814783B2 (ja) | ピラゾロピリジン誘導体 | |
| US12404261B2 (en) | Compounds and compositions for treating conditions associated with cGAS | |
| US8309578B2 (en) | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | |
| JP6964576B2 (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| JP6914933B2 (ja) | ヤヌスキナーゼ、並びにその組成物及びその使用 | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| JP2020526549A5 (https=) | ||
| CN101189233A (zh) | 作为α7烟碱性乙酰胆碱受体的配体的取代二氮杂双环烷烃衍生物 | |
| TW201741313A (zh) | 吡唑並［１，５－ａ］吡嗪－４－基衍生物 | |
| JP6419800B2 (ja) | Ｎｍｄａ受容体活性の調節因子としてのチアゾロピリミジノン | |
| JP6900491B2 (ja) | ピラゾロピリミジン化合物及びその使用方法 | |
| US20160045505A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2021528446A5 (https=) | ||
| JP2020536915A5 (https=) | ||
| EP3209664A1 (en) | Bicyclic heteroaryl amine compounds as pi3k inhibitors | |
| JP2023510874A (ja) | 置換ピラゾロ－ピリミジンおよびその使用 | |
| JP2020520925A5 (https=) | ||
| JP2013518823A5 (https=) | ||
| JP2013538838A (ja) | ７−ヒドロキシ−ピラゾロ［１，５−ａ］ピリミジン化合物およびｃｃｒ２レセプターアンタゴニストとしてのその使用 | |
| JPWO2020146615A5 (https=) | ||
| JP2015528435A5 (https=) | ||
| CN107428750A (zh) | 三唑并吡啶化合物及其使用方法 |